Anxiety disorders Eating disorders Pharmaceuticals 
Psychiatric Times
JULY 7, 2025
MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. Cybin partnered with Osmind to advance psychiatry programs, focusing on CYB003 and CYB004 for major depressive and generalized anxiety disorders.
Mad in America
OCTOBER 18, 2023
For the pharmaceutical industry, the bigger and wider those diseases, the more people who can be diagnosed, and the bigger your markets are. The marketing of medical conditions has become a key plank of pharmaceutical industry marketing. Helping widen the definitions of disease is a key part of marketing those pharmaceutical products.
Expert insights. Personalized for you.
Let's personalize your content